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Abstract: We have developed a fiber-based, video-rate fluorescence diffuse 
optical tomography (DOT) system for noninvasive in vivo sentinel lymph 
node (SLN) mapping. Concurrent acquisition of fluorescence and reference 
signals allowed the efficient generation of ratio-metric data for 3D image 
reconstruction. Accurate depth localization and high sensitivity to 
fluorescent targets were established in to depths of >10 mm. In vivo 
accumulation of indocyanine green (ICG) dye was imaged in the region of 
the SLN following intradermal injection into the forepaw of rats. These 
results suggest that video-rate fluorescence DOT has significant potential as 
a clinical tool for noninvasive mapping of SLN. 
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1. Introduction 
Sentinel lymph node biopsy (SLNB) is the current standard procedure used for prognostic 
staging of cancers and therapeutic guidance. SLNB is a minimally-invasive procedure that 
involves the removal of sentinel nodes (the first lymph nodes that receive drainage from the 
primary tumor) for nodal staging. The location of sentinel lymph nodes (SLNs) is routinely 
determined by injecting radioactive lymphophilic tracer dye intra-operatively around the 
tumor region. The lymphophilic tracer is commonly composed of a radioactive colloid and/or 
optical contrast methylene blue for visual guidance [1,2]. Due to safety issues, a non-invasive 
and non-ionizing method for imaging of metastatic lymph nodes and lymphangiogenesis 
would be preferred. Fluorescence diffuse optical tomography (DOT) is an emerging deep 
tissue (>3 mm) imaging technique that has great potential as an alternative to radioactive 
tracer analysis for noninvasive detection and imaging of the sentinel lymph node. While 
fluorescence DOT often operates on the time scales of minutes to hours, the method also has 
the potential for imaging at higher speeds above the respiratory and cardiac fluctuations, 
allowing it to capture pharmacokinetics and pharmacodynamics of diagnostic and therapeutic 
agents. 
Currently, most fluorescence diffuse optical tomography systems are CCD camera-based 
systems that scan at relatively slow speeds (i.e., frame rates < 0.01 Hz). The slow speed is due 
in part to the method by which ratio-metric data is acquired. Excitation and emission light 
intensity profiles are imaged consecutively, which requires that an interference filter for 
blocking the excitation light to be mechanically inserted between the two scans [3–5]. 
Comparison of sequentially acquired excitation and emission light intensities improves image 
quality through the generation of a normalized ratio-metric data set [6,7]. However, the 
mechanical requirements of sequential scanning slow data collection and pose a challenge for 
real-time imaging. Alternatively, DOT systems developed to image functional absorption 
contrast have used time-  or frequency-encoding of the illumination with broad spectral 
detection to image fast activities (>10 Hz) within the human brain. This style of DOT system 
replaces the CCD-camera acquisition with multiple photodiode detectors in order to take 
advantage of the high dynamic range and high speed of avalanche photodiodes (APDs) [8–
10]. However, the discrete detector DOT approach has not yet been applied to ratio-metric 
data for fluorescence DOT. 
Herein, we aim to improve upon current fluorescence DOT platforms by developing a 
system with expanded dynamic range and faster data acquisition rates. Our video-rate, fiber-
based fluorescence DOT system design is built upon a previously published APD-based 
platform for high-speed DOT [10]. 
The source-detector grid is designed as a contact probe to pre-operatively identify SLNs 
near the tumor region after administration of a fluorescent contrast agent. Biopsy of SLNs 
would follow intra-operatively to enable further histological evaluation for the presence of 
metastatic cells. These studies with a non-specific, but approved, contrast agent ICG will set 
the stage for future work with more specific targeted contrast agents that fluoresce/activate in 
the presence of metastatic cells. 
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imaging by adapting to varying tissue curvatures and performing simultaneous multiple point 
illumination and collection, thus increasing the imaging frame rate. 
We demonstrate the feasibility of in vivo imaging of the dynamics of dye accumulation in 
the region of the sentinel lymph nodes and quantify the accuracy of depth localization and 
sensitivity in tissue-simulating phantoms. These results demonstrate that fiber-based, video-
rate fluorescence DOT is a practical and powerful tool that is well suited to a wide array of 
potential imaging applications, ranging from sentinel lymph node mapping to monitoring 
cancer therapy progression. 
2. Methods 
The generation of ratiometric (fluorescence-to-reference) data for fluorescence DOT 
reconstructions has previously relied on sequentially acquired measurements where the source 
laser is kept at the excitation frequency while a band-pass filter in front of the detector 
alternates between allowing through excitation and emission (fluorescent) light. The detected 
excitation light is then used as a reference to normalize the measured fluorescence. The 
acquisition of such ratiometric data allows reconstructions using the normalized Born 
approximation, which can be implemented to quantify fluorochrome distribution. However, 
while the use of an excitation reference is customary, it is not required. The assumption that 
light at the excitation wavelength acts as a good reference inherently assumes similar optical 
properties at the two wavelengths. And, if this assumption is made, there is no reason why 
light at the fluorescence wavelength could not be used as a reference. With a CCD-based 
system, this would be impractical, as there would be no way to determine the difference 
between the fluorescent and reference light at the same wavelength. However, with APD-
based detection, high speed allows the use of frequency-encoding regimens to separate out 
contributions from different sources. With this encoding scheme, there is no longer any need 
for the hardware-based temporal-encoding of switching a filter in and out of the light beam. 
This paradigm is the basis for the system presented here. 
The fiber-based, video-rate fluorescence DOT system is composed of an alternating grid 
of 12 sources and 13 detectors. The source channels contain 785 nm (Thorlabs DL7140-201S) 
(3.5 mW) and 830 nm (Thorlabs HL8325G) (0.25 mW) laser diodes, with dedicated laser 
diode drivers and control lines for each source, allowing flexible software configurable source 
encoding (frequency- and time-encoding) (Fig. 1A). Light from the sources is coupled into 2.5  
 
 
Fig. 1. Schematic of the video-rate fluorescence DOT hardware. (A) Schematic demonstrating 
frequency-encoding of 830 nm and 785 nm laser diode sources. Both reference and excitation 
light (at distinct frequencies) are incident on the tissue. Light exiting consists of reference, 
excitation, and emission (fluorescent) light. After collimation, the light is passed through a 
narrow band optical filter (F) to block the excitation light (785 nm). The resulting detected 
light, a sum of the reference transmission (I2) and fluorescence emission (I3), is simultaneously 
detected by a single detector. (B) A Fourier transform of  the sum of I2  and I3  provides 
identification of transmission and emission signals from a single detector. 
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photodiodes (Hamamatsu C5460-01) digitized with dedicated  24-bit analog-to-digital 
converters (MOTU HD 192). A narrowband optical filter with center wavelength 830 +/− 10 
nm (CVI) and an out-of-band rejection of OD4 separates the excitation light from fluorescent 
and reference signals. An aspheric lens is used to collimate the light in order to optimize the 
blocking of excitation light by the narrowband interference filter and enhance fluorescent 
signal detection. 
This design provides high instantaneous dynamic range (10
6) and cross-talk rejection 
(10
−6), so that light levels can be detected over many orders of magnitude. With this scheme, 
we acquire frequency-encoded fluorescence emission and reference transmission light levels 
simultaneously at each detector through the individual interference filters optimized for 
fluorescence emission (Fig. 1A). All data are acquired at a frame rate of 30 Hz. A total of 108 
measurements from optode-pairs representing the 1st, 2nd, and 3rd nearest-neighbors are used 
for image reconstruction. 
2.1. Ratiometric reconstruction 
The reference transmission and fluorescent emission light intensities acquired concurrently at 
each detector (Fig.  1B) are used to generate ratio-metric data of fluorescence 
( ) () () ,, emi s i d i emi rr φλ  divided by reference transmission  ( ) () () ,, ref s i d i ref rr φλ . The data are then 
reconstructed using the normalized Born approach to correct for tissue and illumination 
inhomogeneities, which is written in discrete notation as y = Ax with the following definitions 
[6]. 
In the Normalized Born approach  ( )
( )
() ()
() ()
,,
,,
emi s i d i emi
i
ref s i d i ref
rr
y
rr
φλ
φλ

 =
 
. When the bleed-through of 
the filter is accounted for, then the Normalized Born approach becomes 
 
( ) ( )
( )
() () () ()
() ()
,, ,
.
,,
emi s i d i emi bleedthrough s i d i
i
ref s i d i ref
rr rr
y
rr
φ λφ
φλ
 −
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The ratiometric data (y) is generated by measuring the fluorescence light intensity profile 
( ) () () ,, emi s i d i emi rr φλ  at emission wavelength, emi λ , and the reference transmission light intensity 
profile,  ( ) () () ,, ref s i d i ref rr φλ , at the reference wavelength,  ref λ . The i
th  source-detector 
measurement (yi) is associated with source (rs(i)) and detector (rd(i)) locations. 
The bleed through measurement is made in the absence of a fluorescing agent and 
measures the amount of light leakage through the filter. It is determined by 
  ( ) ( ) ( ) ( )
( )
() ()
() () () ()
()
,
, , ,; ;
,
di exc s i exc
bleedthrough s i d i exc s i exc filter ref s i ref
ref s i ref
r
r r r R r where R
r
φλ
φ αφ λ α φ λ
φλ
=× = ×× =  
α captures the optical density of the filter. In this fiber-based fluorescence DOT system there 
are individual detectors and sources, and the sources have separate lasers for both reference 
and excitation. Therefore, the α is calculated separately for each source-detector pairs. To 
calculate  the bleedthrough specific to an  imaging study we derived an estimate the 
bleedthrough of  emi φ  based on  ref φ . Experimentally determined conversion factors (α and R) 
are used to account for the difference in power level between the excitation and reference 
lasers. R is measured using a power meter at source fiber tips of each sources, and 
() di
filter α is the 
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excitation wavelength ( exc λ ) of 785 nm. 
The sensitivity matrix (Ai,j) is created using the analytic solutions for photon density in the 
semi-infinite geometry to obtain the influence of a particular voxel j on every source and 
detector measurement i: 
  ( ) ( )
( )
3
() ()
,
() ()
,, , ,
;
,,
s i j ref j d i emi o
ij j j
o s i d i ref
Gr r Grr s vh
A xN
D Gr r
λλ
λ
=−=∂    
The So is calibration factor while h
3 represents the voxel volume. The Do and v are the 
diffusion coefficient and speed of light in the medium. The two-point Green’s function, G, 
models light transport for the given boundary condition. Optical properties at the reference 
wavelength of µa = 0.1 cm
−1 and µ's = 10 cm
−1 were used to model the optical properties of rat 
and chicken muscles for both in vivo and phantom studies [11–13]. In our case, a semi-infinite 
geometry is implemented.  j x  is the j
th recovered image voxel that contains the fluorescence 
yield  j N ∂  obtained using a Moore-Penrose generalized inverse [8]. 
2.2. Design of phantom studies 
To evaluate the performance of the system, different concentrations of ICG targets in 3 mm 
diameter plastic tubes were prepared and embedded at 7 mm depth in a breast tissue 
mimicking phantom with µa  = 0.1 cm
−1  and µ's  = 10 cm
−1  (Fig. 2A). The breast tissue 
simulating phantom was constructed by mixing 1% Intralipid solution with Black India ink to 
obtain the appropriate absorption and scattering properties [14]. The absorption and reduced 
scattering coefficients are chosen based on previously published values of rats and chicken 
breast optical properties [11–13,15]. The targets contained solutions of indocyanine green 
(Sigma-Aldrich, St Louis, MO) in concentrations ranging from 1 nM to 1 µM. The averaged 
values from regions-of-interest (ROIs) of the reconstructed image were compared to known 
concentrations to evaluate the sensitivity and linear response of the system. 
Analysis of the system’s sensitivity as a function of depth was performed by submerging a 
3 mm diameter plastic tube of 4 µM concentration in a tissue mimicking phantom. Starting at 
a depth of 5.5 mm, the tube was moved in 1.5 mm increments via a vertical stage until the 
middle of the tube reached a depth of 13.5 mm. The depth localization accuracy of the 
fluorescent target and sensitivity were calculated by averaging the intensity of the tube ROI 
and computing the center-of-mass for the different depths acquired. 
2.3. Design of in vivo studies 
We conducted a non-invasive preclinical study of fluorescent sentinel lymph node mapping in 
rats (n = 5) with our fiber-based, video-rate fluorescence DOT system. The hair was shaved 
from the axillary region prior to imaging. In order to test the translational feasibility of the 
system to humans (which will require imaging at depths > 1 cm), we also conducted an 
experiment mimicking a deeper imaging scenario than would normally be available in a rat by 
inserting 8-10 mm of chicken breast tissue between the rat chest wall and the imaging pad 
(Fig. 2B). Imaging through 8-10 mm chicken breast increased the depth of the SLNs to 10-12 
mm, which is deeper than the typical 2 mm where the SLNs are normally located below the 
skin surface in rats. Control images were acquired for 1 minute prior to administration of the 
ICG, and the dynamics of the injection in the axillary region were monitored for 10 minutes 
continuously. 
Animal handling was performed according to the guidelines approved by the Washington 
University School of Medicine Animal Studies Committee for humane care and use of 
laboratory animals. For in vivo imaging, 50 µL of 100 µM ICG was injected intradermally in 
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giving a mixture of ketamine (85 mg/kg) and xylazine (15 mg/kg) for anesthesia. After 
imaging, rats were then euthanized with an overdose of pentobarbital solution (150 mg/kg, IP) 
and the lymph nodes were then resected for verification of ICG uptake. 
For reference and verification of ex vivo  ICG uptake by the lymph nodes, superficial 
fluorescence images were acquired without the layers of chicken breast using the Pearl near-
infrared (NIR) fluorescence imaging system (LiCor Biosciences, Lincoln, NE). 
 
Fig. 2. Schematic of the video-rate fluorescence DOT experimental setup. (A) Schematic of our 
experimental setup with an imaging array and a 3 mm ICG tube embedded in a tissue 
mimicking phantom. (B) Schematic of the placement of the fiber array on a preclinical animal 
model using an 8-10 mm thick chicken breast to simulate a deep tissue imaging situation. 
3. Results 
3.1. System performance analysis with phantom studies 
The Fourier transform of a measurement from a single detector illustrates the use of 
frequency-encoding to separate the emission and reference measurements acquired 
simultaneously (Fig. 1B). Following frequency-decoding, the intensities of both reference 
transmission and emission were retrieved. The data was then used to generate volumetric 
reconstructions of the fluorescence distribution. The reconstructed images from various depths 
suggest that our video-rate fluorescence DOT system has the capability to accurately section 
depths up to 13.5 mm (Fig. 3A). The resolution of the system was tested with simulated data 
for  1 × 1 × 1 mm phantom targets at different depths. The size of the reconstructed 
perturbation is measured with the full width at half maximum (FWHM) of each target's 
reconstruction fluorescence profile. We observe a spatial broadening of the PSF with depth 
(Fig. 3B) with resolutions on the order of 12 mm. The center-of-masses (COMs) of the 
reconstructed fluorescence tubes (Fig. 3A) were computed by averaging the fluorescence 
intensity values for each experimental depth. The linear relationship between the experimental 
and the computed COMs demonstrate the depth localization accuracy up to 13.5 mm (Fig. 
3C). The sensitivity as a function of depth was computed by taking the mean fluorescence 
intensity of the regions-of-interest from reconstructed image for the different depths acquired 
(Fig. 3D). The data demonstrate that the signal intensity drops exponentially with depth, as 
expected. 
The relationship between the true dye concentration and the reconstructed voxel value 
(arbitrary units), is shown in Fig. 3E. The graph confirms the high dynamic range and linear 
response of our system to varying ICG concentrations as measured by the resulting 
fluorescent yield from 1 nM to 1 µM. Values from this phantom analysis are used to generate 
a calibration factor for our in vivo studies. 
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Fig. 3. System sensitivity analysis with phantom studies. (A) Vertical x-z and y-z slices of 
reconstructed experimental data from a fluorescent 3 mm tube target whose center of mass is 
located at 7.5 mm, 10.5 mm, and 13.5 mm depths. The system accurately reconstructs the tube 
shape with some artifact at the optode positions. (B) Point-spread function analysis using a 
simulated image reconstruction. Half-maximum contours of responses for different depths are 
shown. (C) Evaluation of the depth localization accuracy of a phantom target. The system has 
accurate localization from 6 to 13.5 mm. (D) Sensitivity vs depth. The data demonstrate that 
the signal intensity falls off exponentially with depth. (E) The relation between the raw 
reconstructed value and the true concentration of the dye was characterized by titration of ICG 
from 1 nM to 1 uM concentrations in a 3 mm tube. 
3.2. In vivo imaging of the uptake of dye into SLNs 
We performed a pre-clinical in vivo study to evaluate the feasibility of imaging sentinel lymph 
nodes in rats noninvasively. ICG was injected intradermally into the forpaw and the axillary 
region was imaged with DOT. The DOT images of fluorescent lymph dynamics shown at 2 
mm were obtained following injection of the ICG (Fig. 4A) (Media 1). Representative 
dynamics of fluorescent lymphatic fluid accumulation is obtained from a volume of about 30 
mm
3 from the region of the sentinel lymph node of the injection site (Fig. 4B). The mean of 
the background pixels shows no fluctuation associated with the dynamics of fluorescent dye. 
Reflectance fluorescence images were captured using the Pearl NIR fluorescence imaging 
system before sacrificing the animal to confirm  the DOT results (Fig. 4C). Reflectance 
fluorescence images acquired after euthanasia and removal of overlying skin further 
confirmed ICG uptake by the lymph node imaged by DOT (inset on Fig. 4D). 
We repeated the experiment with an increased imaging depth by inserting 8-10 mm of 
chicken breast between the rats (n = 5) and the imaging pad. DOT images of fluorescent 
lymph dynamics were acquired and show that high quality imaging can be obtained even at 
increased depth (Fig. 5A) (Media 2). Time courses of the SLN region as well as background 
pixels demonstrate the representative dynamics of fluorescent lymphatic fluid accumulation 
after the injection (in two individual rats Fig. 5B and averaged over all five rats Fig. 5C). The 
variability in the lymph dynamics and accumulation in the SLNs can be associated with inter- 
and intra-subject variability of the periodic expansion and contraction structures that 
surrounds the lymphatic vessels. The results demonstrate the potential of the video-rate 
fluorescence DOT system to image the in vivo dynamics of dye accumlation in SLNs. 
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Fig. 4. Shallow imaging of lymph dynamics. (A) DOT images of the fluorescence dynamics at 
2 mm depth in a rat following injection of ICG into the left forepaw. (B) Time traces of the 
dynamics of ICG accumulation in the region of the sentinel lymph node (for comparison the 
mean background signal is shown). (C) Reflectance fluorescent imaging of the sentinel lymph 
node region demonstrating fluorescence from the injection site (paws) and the lymph vessels 
leading to axillary lymph nodes (arrow). (D) Reflectance fluorescent image of the rat after 
euthanasia and removal of overlying skin. Inset: fluorescence from ex vivo imaging shows ICG 
uptake in the lymph nodes. 
4. Discussion 
Fiber-based, video-rate fluorescence DOT has the potential to become a powerful and 
practical tool for a broad array of imaging applications, ranging from sentinel lymph node 
mapping to monitoring cancer therapy progress. We demonstrated the feasibility of a 30 Hz 
APD-based fluorescence DOT system. Images of fluorescent targets in tissue mimicking 
phantoms were used to confirm the high dynamic range and linear response of the system and 
the accurate localization of targets in the range of depths from 5.5 to 13.5 mm. As the optical 
properties used in our experiments are higher than those reported for human breast tissues we 
expect the depth sensitivity and dynamic range to be improved in human studies. 
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Fig. 5. Deep (>10 mm) imaging of lymph dynamics. The video rate fluorescence DOT was 
used to image the SLN region in rats through 8-10 mm of chicken breast following ICG 
injection into the rat forepaw. (A) The dynamics in a slice at 11 mm depth from a DOT 
reconstruction. (B) Time traces of the dynamics (for 2 representative rats) of a region around 
the SLN and of the mean of all background pixels. (C) Dynamics of ICG accumulation 
averaged over 5 rats. 
We also successfully demonstrated the in vivo capabilities of the system by noninvasively 
imaging the dynamics of ICG accumulation in a rat. Accumulated dye in the region of the 
sentinel lymph nodes was imaged to a depth of 10-12 mm over a 10 minute time course. 
These results demonstrate the potential for imaging the pharmacokinetics of fluorescent 
diagnostic and therapeutic agents. 
Previous two-dimensional fluorescence reflectance imaging (FRI) has been used to image 
lymph nodes and the lymphatic systems in animal models and cancer patients [16–22]. For 
instance, the lymph dynamics and lymph node images obtained after injection of ICG in 
breast cancer patients show the feasibility of implementing FRI for nodal staging [19]. The 
specificity of the FRI method was further evaluated with an intraoperative FRI system by 
localizing the same SLNs as lymphoscintigraphy in breast cancer patients [20]. This particular 
FRI system is currently on clinical trials for intraoperative SLN mapping in cancer patients 
[16,17,20,23]. While the FRI method is useful, its sensitivity declines quickly with imaging 
depth. 
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improve deep-tissue sensitivity, volumetric localization, resolution, and quantitative accuracy. 
For example, DOT approaches have been used in small animals to image whole bodies [4,24] 
and in humans to image breast [25–28] and brain [29–31] tissues at depths of several 
centimeters. One limitation of our current system for application in humans is the limited field 
of view. The potentential for an expanded system with up to 48 sources and 48 detectors has 
been demonstrated for brain imaging [32]. A higher density imaging array could also 
potentially increase the resolution, particularly at the shallower depths [33]. 
Sentinel lymph node localization is currently performed by administering radiocolloids 
conjugated with blue dye for intraoperative guidance [34]. The potential of implementing 
other organic optical dyes such as fluorescein and indocyanine green has also been 
demonstrated in multiple clinical trials [2,17,19–21,23]. Extensive research is still needed into 
targeted optical dyes. Fiber-based, video-rate fluorescence DOT aided with targeted optical 
dyes could have the potential to assess the cancer status of SLNs non-invasively in order to 
avoid unnecessary surgical procedures. 
Multimodal imaging with fluorescence DOT could also play an important role  in the 
detection and imaging of sentinel lymph nodes for cancer management. DOT could be 
combined with, for example, nuclear imaging to improve the accuracy of DOT images during 
data processing and image reconstruction [35–38]. In addition to a standalone mode (and due 
to the flexibility of the fiber array geometries), video-rate fluorescence DOT also has the 
potential to be combined with handheld ultrasound (US) and/or photoacoustic tomography 
(PAT). Fibers assembled around the periphery of the PAT/US imaging head could provide 
many tracings through the PAT/US imaging volume. A similar approach wherein DOT is 
combined with ultrasound has been demonstrated feasible for imaging breast cancer [39–41]. 
In these scenarios, the fluorescence molecular contrast of DOT would complement the high 
resolution function and anatomical data of PAT and US. 
5. Conclusion 
We have developed a fiber-based, video-rate fluorescence DOT system and demonstrated its 
potential for in vivo imaging. We demonstrated that a 30 Hz APD-based DOT system can be 
operated in fluorescence mode. A fiber-based imaging array was used to image a fluorescent 
target within an agarose phantom and to exhibit our system’s high sensitivity. These results 
confirmed the high dynamic range and linear response of the system and accurate localization 
of various depths. We have also successfully demonstrated the capability of the system for 
sentinel lymph node mapping in rats. Further progress with this technology has the potential 
to provide a useful clinical tool for a wide array of imaging applications, ranging from 
sentinel lymph node mapping to monitoring cancer therapy progress. 
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